Krispel Claudia, Rodrigues Murilo, Xin Xiaoban, Sodhi Akrit
Claudia Krispel, Murilo Rodrigues, Xiaoban Xin, Akrit Sodhi, Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, MD 21287, United States.
World J Diabetes. 2013 Dec 15;4(6):310-8. doi: 10.4239/wjd.v4.i6.310.
By 2050 the prevalence of diabetes will more than triple globally, dramatically increasing the societal and financial burden of this disease worldwide. As a consequence of this growth, it is anticipated that there will be a concurrent rise in the numbers of patients with diabetic macular edema (DME), already among the most common causes of severe vision loss worldwide. Recent available therapies for DME target the secreted cytokine, vascular endothelial growth factor (VEGF). This review focuses on the treatment of DME using the first humanized monoclonal antibody targeting VEGF that has been Food and Drug Administration-approved for the use in the eye, ranibizumab (Lucentis(®)).
到2050年，全球糖尿病患病率将增长两倍多，极大地增加这种疾病在全球范围内的社会和经济负担。由于这种增长，预计糖尿病性黄斑水肿（DME）患者数量也将同时增加，DME已是全球严重视力丧失的最常见原因之一。最近可用的DME治疗方法以分泌的细胞因子血管内皮生长因子（VEGF）为靶点。本综述重点介绍使用首个被美国食品药品监督管理局批准用于眼部的靶向VEGF的人源化单克隆抗体雷珠单抗（Lucentis®）治疗DME。
